Get the Stockscreener App
3.01
4.14%
-0.13
Pre-market:
3.03
0.02
+0.66%
Alaunos Therapeutics Inc stock is traded at $3.01, with a volume of 18,415.
It is down -4.14% in the last 24 hours and down -3.83% over the past month.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
See More
Previous Close:
$3.14
Open:
$3.3099
24h Volume:
18,415
Relative Volume:
0.77
Market Cap:
$6.72M
Revenue:
$6,000
Net Income/Loss:
$-4.03M
P/E Ratio:
-1.3026
EPS:
-2.3107
Net Cash Flow:
$-3.01M
1W Performance:
-7.95%
1M Performance:
-3.83%
6M Performance:
+20.40%
1Y Performance:
+86.88%
1-Day Range:
$3.01
$3.3099
1-Week Range:
$3.01
$3.37
52-Week Range:
$1.3137
$6.20
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Name
Alaunos Therapeutics Inc
Sector
Industry
Phone
(346) 355-4099
Address
501 E LAS OLAS BLVD, FORT LAUDERDALE
Compare TCRT vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
3.01 | 6.72M | 6,000 | -4.03M | -3.01M | -2.3107 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Stock (TCRT) Latest News
Inflation Data: Should value investors consider Alaunos Therapeutics IncQuarterly Investment Review & Community Consensus Trade Signals - baoquankhu1.vn
Weight loss data from obese mice looks promising for Alaunos Therapeutics, but shares drop - MSN
Aug Update: Is Alaunos Therapeutics Inc a cyclical or defensive stockTrend Reversal & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Contrasting Xeris Biopharma (NASDAQ:XERS) and Alaunos Therapeutics (NASDAQ:TCRT) - Defense World
TCRT,MLAC Revenue Breakdown - Finviz
Decliners Report: Can Alaunos Therapeutics Inc stock double in the next year2026 Trading Recap & Accurate Buy Signal Alerts - baoquankhu1.vn
Aug Patterns: Is Alaunos Therapeutics Inc forming a bullish divergence2026 Dividend Review & Weekly Setup with High ROI Potential - baoquankhu1.vn
Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Decreases By 14.3% - Defense World
Shareholder group in Alaunos Therapeutics (TCRT) proposes $7M control-shifting investment - Stock Titan
Will Alaunos Therapeutics Inc benefit from rate cutsJuly 2025 Macro Moves & Safe Capital Growth Plans - baoquankhu1.vn
Alaunos reports early obesity drug data from mouse studies - Investing.com South Africa
TCRT SEC FilingsAlaunos Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop - Benzinga
Alaunos reports findings with ALN-1003 in DIO mouse model - bioworld.com
Alaunos Reports Positive Preclinical Data for Obesity Candidate - TipRanks
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders - The Manila Times
Alaunos Therapeutics reports positive preclinical ALN1003 data showing dose-dependent weight loss, liver improvements - TradingView
Non-hormonal obesity pill helps mice lose weight, improve liver health - Stock Titan
Alaunos (Nasdaq: TCRT) obesity drug ALN1003 cuts weight in mice - Stock Titan
TCRT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Investors seek $7M Alaunos (TCRT) private placement and board seat - Stock Titan
MSN Money - MSN
Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Drops By 14.6% - Defense World
Chart Watch: Can Alaunos Therapeutics Inc stock double in the next yearJuly 2025 Price Swings & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Will Alaunos Therapeutics Inc. face regulatory challengesMarket Volume Summary & Fast Moving Stock Trade Plans - mfd.ru
How does Alaunos Therapeutics Inc. correlate with NasdaqJuly 2025 Reactions & Precise Buy Zone Tips - mfd.ru
Will Alaunos Therapeutics Inc. stock see PE expansion2025 Market WrapUp & Real-Time Buy Signal Alerts - mfd.ru
Published on: 2026-02-11 00:02:19 - baoquankhu1.vn
Alaunos Therapeutics Pivots to Obesity Drug Development in Race Against Time - AD HOC NEWS
Buybacks Report: Is Alaunos Therapeutics Inc a turnaround storyWeekly Earnings Recap & High Win Rate Trade Tips - baoquankhu1.vn
S P Trends: Should value investors consider Alaunos Therapeutics Inc.2025 Key Lessons & Stepwise Trade Signal Guides - mfd.ru
Swing Trade: Is Alaunos Therapeutics Inc a turnaround story2025 Price Targets & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Can Alaunos Therapeutics Inc stock double in the next year - baoquankhu1.vn
Is Alaunos Therapeutics Inc a cyclical or defensive stockTrade Ideas & High Accuracy Swing Trade Signals - baoquankhu1.vn
Fundamentals Check: truyen hinh quan khu mot ky 1 thang 11 ngay 11112019 1087 1July 2025 Market Mood & Low Volatility Stock Suggestions - baoquankhu1.vn
Published on: 2026-01-22 06:26:50 - baoquankhu1.vn
Why Alaunos Therapeutics Inc. stock could see breakout soonJuly 2025 Outlook & Advanced Swing Trade Entry Alerts - bollywoodhelpline.com
Volume Report: Is BioSig Technologies Inc a turnaround storyJuly 2025 Review & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Downgrade Watch: Will Alaunos Therapeutics Inc benefit from rate cutsQuarterly Portfolio Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Why Alaunos Therapeutics Inc. stock could rally in 2025Trade Analysis Report & AI Driven Price Predictions - ulpravda.ru
Market Wrap: Why Alaunos Therapeutics Inc stock is favored by pension fundsJuly 2025 Final Week & AI Optimized Trade Strategies - Bộ Nội Vụ
Published on: 2026-01-09 20:19:14 - Улправда
Why Alaunos Therapeutics Inc. stock is seen as undervalued2025 Price Momentum & Verified High Yield Trade Plans - Улправда
Will Alaunos Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Gainers & Real-Time Buy Signal Notifications - Улправда
Why Alaunos Therapeutics Inc. stock remains on buy listsJuly 2025 Sentiment & Short-Term High Return Ideas - Улправда
Bull Bear: Why Alaunos Therapeutics Inc. stock is favored by pension funds2025 Trading Volume Trends & Weekly Watchlist of Top Performers - Улправда
Alaunos Therapeutics Terminates Engagement With Cantor Fitzgerald - TradingView
Retail Surge: Will Alaunos Therapeutics Inc stock maintain dividend yield2025 Dividend Review & AI Forecasted Entry and Exit Points - moha.gov.vn
Will Alaunos Therapeutics Inc stock attract more institutional investorsM&A Rumor & Accurate Entry/Exit Alerts - moha.gov.vn
Alaunos Therapeutics reaches settlement with MD Anderson over unpaid invoices - Investing.com Canada
Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer - TipRanks
Alaunos Therapeutics Inc Stock (TCRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):